OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
In the past decades we have seen the rise and fall of a number of promising therapies for Duchenne muscular dystrophy. Despite huge efforts in the field only a few have made it through approval by regulatory agencies. Two main reasons of failure are :1) a limited efficacy of the compounds in development and 2) issues in trial design (the selection of outcome measures and endpoints, selection of patient population). In this seminar we will discuss the issues in clinical development in DMD and explore how we could potentially improve clinical trial design.
